Patriot Financial Group Insurance Agency LLC Buys 15,733 Shares of AbbVie Inc. $ABBV

Patriot Financial Group Insurance Agency LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 105.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,644 shares of the company’s stock after purchasing an additional 15,733 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in AbbVie were worth $6,665,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Chelsea Counsel Co. acquired a new stake in shares of AbbVie in the 3rd quarter valued at $26,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the fourth quarter worth $28,000. Westend Capital Management LLC acquired a new position in shares of AbbVie during the fourth quarter valued at $29,000. Imprint Wealth LLC lifted its stake in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX bought a new position in AbbVie in the third quarter valued at about $31,000. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

ABBV opened at $251.52 on Monday. The firm’s fifty day moving average is $215.16 and its two-hundred day moving average is $219.16. The firm has a market cap of $444.38 billion, a PE ratio of 123.90, a price-to-earnings-growth ratio of 0.77 and a beta of 0.32. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $253.35.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the previous year, the business earned $2.46 EPS. The firm’s revenue was up 12.4% on a year-over-year basis. Equities analysts forecast that AbbVie Inc. will post 14.28 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABBV. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Guggenheim reaffirmed a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target for the company in a research report on Thursday, April 30th. Finally, William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.81.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.